Katrina enabled Ochsner Baptist to hit the "reset button," said Ochsner Health System CEO Warner Thomas.» Read More
Public health officials implored parents to vaccinate their children against the measles in a Tuesday Congressional hearing.
As health-care out-of-pocket costs rise, people can save by shopping around, but significant transparency hurdles remain.
Dr. Gail Shust, an infectious disease specialist, tells CNBC, "It really is not just a personal choice but a public health issue."
Sanofi launched an inhalable insulin in the U.S. in a potential boost for its flagging diabetes drug sales and for patient quality of life.
While vaccines are a good thing, it's an issue of personal freedom, Sen. Rand Paul told CNBC.
The $1.08 trillion budget sought by federal health officials includes a request they be able to negotiate some drug prices for Medicare.
Web-based insurance brokers don't have a desired tool to help boost Obamacare enrollments despite asking for it for more than a year.
The number of people on Medicaid has significantly increased, nowhere more so than in states that have loosened eligibility rules.
H&R Block's William Cobb says he's seeing a surge in business as Americans struggle to resolve health-care-related tax issues.
An appeals court that POM Wonderful cannot advertise that its juices treat or prevent heart disease unless it can prove that the assertions are true.
Congressional Republicans are creating a group to draw up a replacement for the still controversial health-care reform law.
Oil prices are in the midst of a prolonged slump, squeezing bottom lines everywhere. How do sovereign wealth funds cope?
A Massachusetts-based nonprofit organization is looking to get really personal, and it's paying good money for healthy stool samples.
President Obama will dedicate $215 million in his budget request to a program that will target the underlying cause of disease.
The drugmaker has engaged in $100 billion of M&A in the last year, but CEO Brent Saunders told CNBC it is committed to innovation.
Eli Lilly has been on a roller-coaster ride in the wake of patent expirations, CEO John Lechleiter tells CNBC.
Two new studies discuss turning stem cells into hair cells and transplanting them onto bald spots.
The sheer volume and pace of biotech offerings are causing some to question whether the sector is nearing the end of its years of buoyancy.
Measles is not a disease you should fool with, warned Vanderbilt University's Dr. William Schaffner.
Researchers found that feeding a group of children a form of beneficial bacteria helped them overcome a potentially fatal food allergy.
Get the best of CNBC in your inbox